Combination therapy for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with persistent, recurrent, or metastatic cervical cancer (FIGO stage IVB) that cannot be cured with surgery or radiation.
- Your cancer type is squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You have not received any systemic therapy (like chemotherapy) for recurrent or metastatic cervical cancer.
- You have at least one tumor that can be measured on scans.
- You are willing to provide a tumor tissue sample (either from a recent biopsy or an archived one).
- You are in generally good health (able to care for yourself, up and about more than 50% of the time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.